Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal preparation containing hyaluronic acid, medicinal transdermal patch and preparation method of medicinal transdermal patch

A technology for pharmaceutical preparations and hyaluronic acid, which is applied in the field of medicine to achieve the effects of reducing irritation, improving bioavailability and reducing adverse reactions

Active Publication Date: 2020-12-11
江苏一全药业有限公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing transdermal patches are still difficult to achieve long-lasting (up to 5-7 days) effective release, and new absorption enhancers may bring new risks to the human body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal preparation containing hyaluronic acid, medicinal transdermal patch and preparation method of medicinal transdermal patch
  • Medicinal preparation containing hyaluronic acid, medicinal transdermal patch and preparation method of medicinal transdermal patch
  • Medicinal preparation containing hyaluronic acid, medicinal transdermal patch and preparation method of medicinal transdermal patch

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A1

[0082] (1) Prepare packaged medicine

[0083] Dissolve 0.28g of lorazepam in an aqueous solution containing 0.42g of hyaluronic acid (molecular weight: 11300) represented by formula (1), and then carry out the process at an air inlet temperature of about 150°C and an outlet temperature of about 80°C. Spray-dry to obtain lorazepam hyaluronic acid coating with an average particle size of 268nm.

[0084] (2) Ingredients

[0085] Encapsulated drug: prepared in this embodiment;

[0086] Unpacked drug: Lorazepam, 0.1g;

[0087] Transdermal absorption enhancer: isopropyl myristate, 0.57g;

[0088] Drug-loaded matrix: 5.6g in total, of which 3.92g is 2852 pressure-sensitive adhesive (containing carboxyl group), 1.12g is 2287 pressure-sensitive adhesive (containing hydroxyl group), 1.12g is 4098 pressure-sensitive adhesive (no functional group) 0.56g;

[0089] Solvent: propylene glycol, 0.4 g.

[0090] (3) preparation of drug transdermal patch

[0091] Mix and dissolve the unwra...

Embodiment A2

[0094] (1) Prepare packaged medicine

[0095] Dissolve 0.25g of lorazepam in an aqueous solution containing 0.45g of hyaluronic acid (molecular weight: 7800) represented by formula (1), and then carry out the process at an inlet temperature of about 150°C and an outlet temperature of about 80°C. Spray-dry to obtain lorazepam hyaluronic acid coating with an average particle size of 396nm.

[0096] (2) Ingredients

[0097] Encapsulated drug: prepared in this embodiment;

[0098] Unpacked drug: Lorazepam, 0.1g;

[0099] Transdermal absorption enhancer: isopropyl myristate, 0.42g;

[0100] Drug-loading matrix: a total of 6g, of which 4.8g is 235A pressure-sensitive adhesive (containing carboxyl group), 0.6g is 2516 pressure-sensitive adhesive (containing hydroxyl group), 0.6g is 4098 pressure-sensitive adhesive (no functional group) 0.6g;

[0101] Solvent: butylene glycol, 0.3 g.

[0102] (3) preparation of drug transdermal patch

[0103] Mix and dissolve the unwrapped drug...

Embodiment A3

[0106] (1) Prepare packaged medicine

[0107] Dissolve 0.22g of lorazepam in an aqueous solution containing 0.26g of hyaluronic acid (molecular weight: 13,200) represented by formula (1), and then carry out the process at an inlet air temperature of about 150°C and an outlet air temperature of about 80°C. Spray-dry to obtain lorazepam hyaluronic acid coating with an average particle size of 314nm.

[0108] (2) Ingredients

[0109] Encapsulated drug: prepared in this embodiment;

[0110] Unpacked drug: Lorazepam, 0.1g;

[0111] Transdermal absorption enhancer: Span 20, 0.70g;

[0112] Drug-loaded matrix: 4.67g in total, of which 2.8g is 2852 pressure-sensitive adhesive (containing carboxyl group), 1.87g is 2516 pressure-sensitive adhesive (containing hydroxyl group);

[0113] Solvent: n-butanol, 0.5 g.

[0114] (3) preparation of drug transdermal patch

[0115] Mix and dissolve the unwrapped drug prepared in this example with a solvent, and then fully mix with the wrapped...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of medicine, in particular to a medicinal preparation, a medicinal transdermal patch containing the medicinal preparation and a preparation method of the medicinal transdermal patch. The medicinal preparation comprises coated medicine and uncoated medicine; the coated medicine comprises medicine A and an inclusion material coating the medicine A; the inclusion material contains hyaluronic acid and / or a derivative of the hyaluronic acid; the uncoated medicine is medicine B; and the medicine A and the medicine B are the same or different. The medicinal preparation and the medicinal transdermal patch provided by the invention have the advantages that an effective dose of medicine can be stably and durably (capable of reaching 7 days) released, and in addition, the controllability is high, so that the medication requirements of patients of different degrees can be met.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical preparation, a drug transdermal patch containing the pharmaceutical preparation and a preparation method thereof. Background technique [0002] External treatment is a commonly used method in clinical practice. In the early days, it was mostly in the form of Chinese herbal plasters, which were used to apply acupoints or local injuries to achieve therapeutic effects. This treatment method is simple and easy to operate, and has a high degree of patient acceptance. [0003] In addition, for Western medicines that are traditionally taken orally or injected, transdermal patches have appeared in recent years to replace oral or injected. On the other hand, it can increase patient acceptance. However, it is still difficult for the drug to release an effective dose through the stratum corneum of the skin, and the penetration dose, stability and duration have not been ideal. In t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/70A61K47/36A61K47/69A61K47/32A61K47/26A61K47/12A61K47/10A61K47/14A61K47/22A61K31/5513A61P25/22
CPCA61K9/7023A61K31/5513A61K47/10A61K47/12A61K47/14A61K47/22A61K47/26A61K47/32A61K47/36A61K47/6949A61P25/22
Inventor 全丹毅
Owner 江苏一全药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com